Dermapharm Holding SE の最大収益セグメントは Branded Pharmaceuticals で、最新の利益発表における収益は 617,158,000 です。地域別に見ると、Germany が Dermapharm Holding SE の主要市場であり、収益は 696,402,000 です。
Dermapharm Holding SEは収益を上げていますか?
いいえ、最新の財務諸表によると、Dermapharm Holding SEの純損失は$0です。
Dermapharm Holding SEに負債はありますか?
いいえ、Dermapharm Holding SEの負債は0です。
Dermapharm Holding SEの発行済株式数は何株ですか?
Dermapharm Holding SEの総発行済株式数は0株です。
主要データ
前終値
$47.69
始値
$47.69
当日レンジ
$47.69 - $47.69
52週レンジ
$39.56 - $53
取引高
100
平均取引高
3
配当利回り
--
1株当たり利益(TTM)
3.05
時価総額
$2.3B
Dermapharm Hldg SEとは何ですか?
Dermapharm Holding SE engages in the development, manufacture and market of patent-free pharmaceutical products. The firm operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. The company holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The firm offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. The company is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.